Trastuzumab: A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Author： Garnock-Jones Karly P.   Keating Gillian M.   Scott Lesley J.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.2, 2010-01, pp. : 215-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

By Essers Brigitte A.B.   Seferina Shanley C.   Tjan-Heijnen Vivianne C.G.   Severens Johan L.   Novák Annoesjka   Pompen Marjolein   Oron Ulrich H.   Joore Manuela A.  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 375-380

Blackwell Publishing

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

The Croatian government is to pay for early-stage human epidermal growth factor receptor 2-positive breast cancer patients to receive Roche's Herceptin

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 526, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite